The 2026 review should not change routine care yet for adults with persistent acne because spironolactone already has a clear role for women, while metformin and bicalutamide lack large general-acne trials. Persistent acne means facial breakouts that continue into adulthood and often need systemic treatment, meaning pills that act throughout the body. The review describes a shift beyond isotretinoin toward repurposed pills such as sarecycline, spironolactone, and metabolic agents because isotretinoin carries safety limits and monitoring burden, according to the Dermatology Times review. That shift matters mainly as an antibiotic-sparing direction, not as a new prescription standard.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the review signals for adults
- Who can use spironolactone now?
- Why metformin stays narrow
- Why bicalutamide is not routine
What the review signals for adults
The interest in repurposed systemics reflects a practical problem. Isotretinoin works well for severe acne but demands strict safety checks and follow-up. Dermatologists want options that lower antibiotic use and fit long-term adult disease.
For most adults, that means staying with proven topicals, hormonal evaluation where relevant, and established systemics. Metabolic drugs and androgen blockers remain selective tools, not replacements. The review widens discussion without supplying the trial strength needed to reset guidelines.
Who can use spironolactone now?
Spironolactone is a blood-pressure pill used in acne for its antiandrogen effect. Brigham acne expert John Barbieri reports it decreases sebaceous-gland activity and ranks among the more effective systemic options for women, but its antiandrogen effects mean it is generally usable only in women.
The SAFA trial randomized 410 women with persistent facial acne at 10 UK centres to spironolactone or placebo and found significantly clearer skin with spironolactone, with benefit widening from week 12 to week 24, according to the NIHR trial report. The American Academy of Dermatology 2024 acne guidelines conditionally recommend oral spironolactone for acne on moderate-certainty evidence, with potassium testing only for patients with hyperkalemia risk factors, according to the AAD guideline summary. Ask about fit if you are an adult woman with persistent jawline breakouts, flare around periods, or intolerance to antibiotics:.
- current acne pattern, duration, and prior systemic use
- blood pressure, potassium, kidney issues, and pregnancy plans
- other drugs that raise potassium or affect hormones
Why metformin stays narrow
Metformin is a diabetes drug that improves insulin sensitivity. In acne care, interest centers on women with polycystic ovary syndrome, a hormonal condition with excess androgens, irregular periods, and often insulin resistance. The Journal of Clinical and Aesthetic Dermatology reported reduced acne scores over 6 months in women with PCOS and papulopustules, meaning red bumps with pus. Benefit was linked to lower ovarian hyperandrogenism and IGF-1/androgen signaling.
That supports use mainly in PCOS or insulin-resistant patients, not in all adult acne. A practical step is to check for irregular periods, excess hair growth, scalp shedding, weight change, and family diabetes history. Share those details with primary care and dermatology together. Treatment of acne alone rarely justifies metformin without metabolic signs.
Why bicalutamide is not routine
Bicalutamide is an androgen-receptor blocker approved for prostate cancer. It blocks male-hormone signals that can drive oil, acne, seborrhea, and hirsutism, meaning excess coarse hair in androgen-sensitive areas. The Journal of the American Academy of Dermatology reported acne, seborrhea, and hirsutism improvement in small female hair-loss and hyperandrogenism case series.
Evidence in acne remains limited to observational reports, without large controlled acne trials. Safety limits use sharply. The FDA bicalutamide label states it is contraindicated in women and pregnancy and warns of severe hepatic injury and fatal hepatic failure, requiring baseline and periodic transaminase monitoring, according to the FDA prescribing information. Do not seek it for ordinary persistent acne, and discuss contraception, liver history, alcohol use, and all liver-affecting drugs before any specialist considers it.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne